Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Gounden, Verena ^a,b   van Niekerk, Chantal ^a,b   Snyman, Tracy ^a,b   George, Jaya A ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; GUANINE; THREONINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HALLUCINATION; HEADACHE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SOUTH AFRICA; SUICIDAL IDEATION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 77955694290     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-32     Document Type: Article

References (31)

1. UNAIDS 2008 Report on the global AIDS epidemic, August 2008. , http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp
2. FDA drug information sheet. , http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020972s026,021360s013lbl.pdf
3. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma concentrations can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001, 15:71-75. 10.1097/00002030-200101050-00011, 11192870.
4. Haas D, Ribaudo HJ, Kim RB, Camlin T, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004, 18:2391-2400.
5. Flexner D. Advances in HIV Pharmacology: Protein Binding, Pharmacogenomics and Therapeutic Drug Monitoring. Top HIV Med 2003, 11:40-44.
6. Ward BA, Gorski JC, Jones DR, Hall SD, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol ExpTherapy 2003, 306:287-300.
7. Yamano S, Nhambura PA, et al. cDNA cloning and sequence and cDNA-directed expression of human P450 iiB1. Biochemistry 1989, 28:7340-7348. 10.1021/bi00444a029, 2573390.
8. Wang J, Sonnenerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism if the HIV drug efavirenz. Pharmacogenet Genomics 2006, 16:191-198. 10.1097/01.fpc.0000230119.34205.8a, 16495778.
9. Rotger M, Tegude H, Colombo S, et al. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrationsin HIV-infected Individuals. J Clin Pharm Ther 2007, 81:557-566.
10. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy efavirenz. Pharmacogenet Genomics 2005, 15:861-879. 10.1097/01213011-200512000-00004, 16272958.
11. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006, 62:267-275. 10.1007/s00228-005-0092-9, 16506047.
12. Nyakutira C, Röshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008, 64:357-365. 10.1007/s00228-007-0412-3, 18057928.
13. The Royal College of Psychiatrists, Alcohol related disorders. , http://www.rcpsych.ac.uk/default.aspx?page
14. American National Institute of Health, Division for Acquired Immune Deficiency Syndrome Toxicity Grading, August 2005. , http://www.fda.gov/OHRMS/DOCKETS/dockets/05d0155/05D-0155_emc-000002-02.pdf
15. Krouwer JS. Preliminary Evaluation of Quantitative Clinical Laboratory Methods, Approved Guideline - EP10A3. 2006, CLSI/NCCLS, 3.
16. Clifford D, Evans S, Yang Y, et al. Impact of Efavirenz on Neuropsychiatric Performance and Symptoms in HIV-infected individuals. Ann Intern Med 2005, 143:714-721.
17. Online Encyclopaedia for Genetic Epidemiology Studies. , http://www.genes.org.uk/software/hardy-weinberg.shtml
18. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007, 45:1230-7. 10.1086/522175, 17918089.
19. Fumaz CR, Munoz-Moreno BS, Molto J, et al. Long-term Neuropsychiatric disorders on Efavirenz based approaches: Quality of life, Psychological issues and adherence. JAIDS 2005, 38:560-565.
20. Ståhle L, Moberg L, Svensson J, et al. Efavirenz Plasma Concentrations in HIV-Infected Patients Inter- and Intraindividual Variability and Clinical Effects. Ther Drug Monit 2004, 26:267-270. 10.1097/00007691-200406000-00008, 15167626.
21. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS society - USA panel. JAMA 2004, 292:251-265. 10.1001/jama.292.2.251, 15249575.
22. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001, 40:893-905. 10.2165/00003088-200140120-00002, 11735608.
23. Pillay V, Pillay C, Kantor R, et al. HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy. AIDS Res Hum Retroviruses 2008, 24:1449-1454. 10.1089/aid.2008.0180, 19000027.
24. Wyen C, Hendra H, Hoffman C, et al. Impact of CYP2B6 983T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008, 61:914-8. 10.1093/jac/dkn029, 18281305.
25. Kwara A, Lartey M, Sagoe KWC, et al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009, 23:2101-2106. 10.1097/QAD.0b013e3283319908, 19779319.
26. di Iulio J, lie Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009, 19:300-309. 10.1097/FPC.0b013e328328d577, 19238117.
27. López-Cortés L, Ruiz-Valderas R, Marín-Niebla A, et al. Therapeutic Drug Monitoring of Efavirenz: Trough Levels Cannot Be Estimated on the Basis of Earlier Plasma Determinations. JAIDS 2005, 39:551-556.
28. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003, 73:20-30. 10.1067/mcp.2003.22, 12545140.
29. Langmann P, Weissbrich B, Desch S, et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pre-treated HIV-1 infected patients. Eur J Med Res 2002, 7:309-314.
30. López-Cortés LF, Alarcón A, Viciana P, et al. Efavirenz plasma concentrations and efficiency. AIDS 2001, 15:1192-1193. 10.1097/00002030-200106150-00022, 11416729.
31. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Co administered With Rifampicin-Based Antitubercular Therapy. JAMA 2008, 300:530-9. 10.1001/jama.300.5.530, 18677025.